Payment overview · 2025
General Payments
$1,001.24
44 reported records · 13 companies
Healthcare provider profile · identity verified
Lance Waldmeier
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · VINTON, LA · NPI 1750386140
Verified facts
What the public records show
CMS Open Payments records show Lance Waldmeier received $1,001.24 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $212.67 | 21.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.02 | 19.5% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $117.94 | 11.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.61 | 11.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.31 | 8.2% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.49 | 7.8% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.31 | 6.7% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.66 | 3.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.32 | 2.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.25 | 2.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.50 | 2.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.30 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.86 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,001.24 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $181.26 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.11 | 15 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $117.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $85.01 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.31 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.49 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $67.31 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $53.60 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.91 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
85 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 84 |
| Lisinopril | Lisinopril | 334 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 330 | 89 |
| Gabapentin | Gabapentin | 281 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 238 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 235 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 66 |
| Montelukast Sodium | Montelukast Sodium | 220 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 50 |
| Omeprazole | Omeprazole | 194 | 48 |
| Metformin Hcl Er | Metformin Hcl | 181 | 46 |
| Alprazolam | Alprazolam | 160 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 43 |
| Losartan Potassium | Losartan Potassium | 139 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 49 |
| Furosemide | Furosemide | 135 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 25 |
| Meloxicam | Meloxicam | 114 | 34 |
| Celecoxib | Celecoxib | 102 | 24 |
| Eliquis | Apixaban | 98 | 17 |
| Buspirone Hcl | Buspirone Hcl | 95 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 25 |
| Famotidine | Famotidine | 89 | 20 |
| Trulicity | Dulaglutide | 86 | 16 |
| Irbesartan | Irbesartan | 85 | 28 |
| Jardiance | Empagliflozin | 85 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 22 |
| Mounjaro | Tirzepatide | 77 | 15 |
| Lorazepam | Lorazepam | 73 | 15 |
| Metformin Hcl | Metformin Hcl | 69 | 19 |
| Carvedilol | Carvedilol | 65 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 22 |
| Clonidine Hcl | Clonidine Hcl | 63 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 15 |
| Simvastatin | Simvastatin | 61 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 19 |
| Meclizine Hcl | Meclizine Hcl | 57 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 16 |
| Trazodone Hcl | Trazodone Hcl | 55 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 13 |
| Farxiga | Dapagliflozin Propanediol | 51 | 13 |
| Sertraline Hcl | Sertraline Hcl | 51 | 16 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 44 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 18 |
| Linzess | Linaclotide | 42 | 12 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 33 | 11 |
| Mupirocin | Mupirocin | 33 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 13 |
| Belsomra | Suvorexant | 31 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 28 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 16 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Estradiol | Estradiol | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,001.24 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CARDIOMEMS, FANAPT, FARXIGA, IBSRELA, JARDIANCE, NEXLETOL, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error